Ledger.Open graph →
SEC Form D · Amendment · filed September 4, 2012

INTERCEPT PHARMACEUTICALS INC

Offering
$50.0M
Sold
$30.0M
Exemption
Industry
Biotechnology
Location
NEW YORK, NY
Type

People & firms on this filing (17)

Barbara Duncan · New York, NYExecLuciano Adorini · New York, NYExecDavid Shapiro · New York, NYExecMark E. Pruzanski · New York, NYExec · DirectorPaolo Fundaro · New York, NYDirectorNicole Williams · New York, NYDirectorJonathan T. Silverstein · New York, NYDirectorLorenzo Tallarigo · New York, NYDirectorHoward Schwartz · Norwalk, CTExec · DirectorFranklin J. Trotter · Hampton, NHExecAndrew Garman · Hampton, NHDirectorJohn Wallace · Hampton, NHDirectorJames W. Bennett · Hampton, NHExecWillie E. Woods · New York, NYExecLloyd M. Metz · New York, NYDirectorLorenzo Tallarigo · New York, NYDirectorKlaus Veltinger · New York, NYDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗